about
Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuseNeonatal Fc receptor mediates internalization of Fc in transfected human endothelial cellsTRIM21: a cytosolic Fc receptor with broad antibody isotype specificityFusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersCustomizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applicationsIleal Immunoglobulin Binding by the Neonatal Fc Receptor: A Previously Unrecognized Mechanism of Protection in the Neonatal Rat Model of Necrotizing Enterocolitis?Antibodies as therapeutic agents: vive la renaissance!Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptorA modeling analysis of the effects of molecular size and binding affinity on tumor targeting.PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.Novel therapeutic agents under investigation for malignant melanoma.Placental Malaria: Decreased Transfer of Maternal Antibodies Directed to Plasmodium falciparum and Impact on the Incidence of Febrile Infections in Infants.The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingAntibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.Designing immunotherapies to thwart drug abuse.Role of Fc Receptors as a therapeutic target.Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.Oral tolerance in neonates: from basics to potential prevention of allergic disease.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.Assessments of antibody biodistribution.Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.Influence of the duration of intravenous drug administration on tumor uptake.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Targeted Intracellular Delivery of Antibodies: The State of the Art
P2860
Q24632128-A3464FE7-F8D2-4673-82E5-F2DBC0F6D21DQ24651849-BE1F2795-3ECF-4D79-8443-B5956A25D133Q26779753-CB4BC161-C7D6-4353-A0D1-28C52564E49FQ26801319-54FE8A0C-5337-45F9-9FAB-DF841E75CA3DQ26864041-082A2224-721C-491A-8CAC-367F8EF9A409Q30411401-BF8EA3AC-3E74-487A-BAC7-633AB6DE3796Q33193524-4B38E1DC-5449-4FA1-AB5F-3E7CC81E47ECQ33224048-FFC03BDA-1A18-4DC9-9597-071113BC3250Q33431320-0AC1DD79-FC16-4AE1-87A6-85CA50073C48Q33519532-C76D6DDB-DA59-4DE6-87E5-486674E56615Q33573587-BA1ABBFD-B790-492B-82D2-9EAE6DAAA9FAQ33835328-7B4AFC03-AD5E-4A88-B5D2-27412539D984Q33896659-8E90FA7C-73E7-4FBB-A55F-5F7DB11B8BDBQ34199603-17D4833F-1A00-46E5-B95F-2F65212DBC21Q34684399-0B024284-6C85-46A2-BCB3-BEBF7216452BQ35194805-A114AA6F-A32E-4242-B905-32AEA6F7EDF5Q35207632-C739440A-F2CD-4952-A443-578C8AC83037Q35876806-10206B9F-E64F-4DE9-9C60-69CFD6580C04Q36536590-1FA8E367-BAE4-4EF3-8522-03BA0AFBF3AFQ37138332-5460DF5D-09B4-4C0E-AC3E-66F64EF5A655Q37187003-7474F1FB-0D82-4502-974A-D810B16F9CB7Q37346613-FDC4E436-29FC-40A3-9C40-32A23634F532Q37411578-B12B1884-73EB-4F56-99BE-9354961B3BF5Q37581834-829818C4-1FBA-4BDC-80F7-B8FEBED75DECQ37756521-5303FC25-2CCD-4184-B6B5-504B617F6EB1Q38072598-90EC903F-D098-4C55-9E0F-EE6477EF475EQ38097514-B5552E68-EE8C-44E2-8F6E-5103F64C3BC8Q38364460-0224674E-37CF-4523-A21C-DB0BC9385990Q38605894-4094D0E5-BAAE-4815-B260-91252D1F23F6Q38696361-424D70CD-BBDF-413D-9426-296CF6453062Q38711889-A460D731-3D9A-491C-9476-CC254D3BFA53Q38798137-9252B53F-6F94-4CD1-953B-64C8468777A9Q39650162-A8244A45-D38E-4759-A89D-FE56008FB139Q40309222-A0E54F3F-6028-4FBA-9B2E-94D27B7F787AQ42000964-D46EB99C-074D-4150-BEB2-2CD8C125F863Q42094317-0C097673-689B-4FBA-8868-93A0EDECD5BFQ50091855-55825094-115B-4C26-94DC-73A7C723DD58Q58566968-2EC0FCAD-73F5-400C-B9B0-119A6A209525
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Transcytosis and catabolism of antibody.
@ast
Transcytosis and catabolism of antibody.
@en
Transcytosis and catabolism of antibody.
@nl
type
label
Transcytosis and catabolism of antibody.
@ast
Transcytosis and catabolism of antibody.
@en
Transcytosis and catabolism of antibody.
@nl
prefLabel
Transcytosis and catabolism of antibody.
@ast
Transcytosis and catabolism of antibody.
@en
Transcytosis and catabolism of antibody.
@nl
P356
P1433
P1476
Transcytosis and catabolism of antibody.
@en
P2093
E Sally Ward
Victor Ghetie
P2888
P304
P356
10.1385/IR:25:2:097
P577
2002-01-01T00:00:00Z
P6179
1042919845